Erlotinib: A Targeted Anticancer Drug

Conclusion: In nonclinical toxicology studies, the drug has not shown any results of fertility impairment, carcinogenesis or mutagenesis. Though the EGFR-TKIs have shown great clinical significance, the development of drug resistance has also been reported by the patients. The resistance for EGFR-TKIs can occur through any of the several mechanisms involved like secondary mutation (T790M), ATP binding cassette transporter effusion, alteration of the downstream pathways, etc. This article reviews the safety and efficacy of erlotinib along with chemistry, mechanism, pharmacokinetics, drug interactions and resistance to the drug.
Source: Current Cancer Therapy Reviews - Category: Cancer & Oncology Source Type: research